<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_nDbU47b">Birth Prevalence of Sickle Cell Disease and County-Level Social Vulnerability -Sickle Cell Data Collection Program, 11 States, 2016-2020</title>
				<funder>
					<orgName type="full">National Institute of Neurological Disorders and Stroke</orgName>
					<orgName type="abbreviated">NINCDS</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100000065</idno>
				</funder>
				<funder>
					<orgName type="full">Sickle Cell Disease Subcommittee</orgName>
				</funder>
				<funder>
					<orgName type="full">Duke Adult and Pediatric Sickle Cell Program</orgName>
				</funder>
				<funder>
					<orgName type="full">National Heart, Lung, and Blood Institute</orgName>
					<orgName type="abbreviated">NHLBI</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100000050</idno>
				</funder>
				<funder>
					<orgName type="full">American Society of Hematology Sickle Cell Learning Community Meeting and Sickle Cell Disease Association of America Meeting</orgName>
				</funder>
				<funder>
					<orgName type="full">American Thrombosis Hemostasis Network Data Summit</orgName>
				</funder>
				<funder>
					<orgName type="full">Veterans Administration and Duke University Clinical and Translational Science Institute</orgName>
				</funder>
				<funder>
					<orgName type="full">National Institutes of Health</orgName>
					<orgName type="abbreviated">NIH</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100000002</idno>
				</funder>
				<funder>
					<orgName type="full">HRSA Southeast Region Coordinating Center Sickle Cell Treatment Demonstration Program</orgName>
				</funder>
				<funder>
					<orgName type="full">American Society of Hematology Research Collaborative Data Hub Oversight Group</orgName>
				</funder>
				<funder ref="#_yqGYsaC">
					<orgName type="full">Health Resources and Services Administration</orgName>
					<orgName type="abbreviated">HRSA</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100000102</idno>
				</funder>
				<funder>
					<orgName type="full">North Carolina State Department of Health Sickle Cell Syndrome Program</orgName>
				</funder>
				<funder>
					<orgName type="full">Novo Nordisk Independent Medical Education Activity</orgName>
				</funder>
				<funder>
					<orgName type="full">Agios Medical Education Program</orgName>
				</funder>
				<funder>
					<orgName type="full">American Society of Hematology</orgName>
					<orgName type="abbreviated">ASH</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100001422</idno>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Mariam</forename><surname>Kayle</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Audrey</forename><forename type="middle">L</forename><surname>Blewer</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Wei</forename><surname>Pan</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Jennifer</forename><forename type="middle">A</forename><surname>Rothman</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Carri</forename><forename type="middle">S</forename><surname>Polick</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, PhD</roleName><forename type="first">Joshua</forename><surname>Rivenbark</surname></persName>
						</author>
						<author>
							<persName><roleName>MS</roleName><forename type="first">Elliott</forename><surname>Fisher</surname></persName>
						</author>
						<author>
							<persName><roleName>MS</roleName><forename type="first">Camila</forename><surname>Reyes</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, PhD</roleName><forename type="first">John</forename><forename type="middle">J</forename><surname>Strouse</surname></persName>
						</author>
						<author>
							<persName><roleName>MHS</roleName><forename type="first">Shelby</forename><surname>Weeks</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Jay</forename><forename type="middle">R</forename><surname>Desai</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Angela</forename><forename type="middle">B</forename><surname>Snyder</surname></persName>
						</author>
						<author>
							<persName><roleName>MS</roleName><forename type="first">Mei</forename><surname>Zhou</surname></persName>
						</author>
						<author>
							<persName><roleName>MBBS</roleName><forename type="first">Ankit</forename><surname>Sutaria</surname></persName>
						</author>
						<author>
							<persName><roleName>MPH</roleName><forename type="first">Jhaqueline</forename><surname>Valle</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Sophia</forename><forename type="middle">S</forename><surname>Horiuchi</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Marci</forename><forename type="middle">K</forename><surname>Sontag</surname></persName>
						</author>
						<author>
							<persName><roleName>MPH</roleName><forename type="first">Joshua</forename><forename type="middle">I</forename><surname>Miller</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Ashima</forename><surname>Singh</surname></persName>
						</author>
						<author>
							<persName><roleName>MS</roleName><forename type="first">Mahua</forename><surname>Dasgupta</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Isaac</forename><forename type="middle">A</forename><surname>Janson</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Najibah</forename><surname>Galadanci</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Sarah</forename><forename type="middle">L</forename><surname>Reeves</surname></persName>
						</author>
						<author>
							<persName><roleName>MPH</roleName><forename type="first">Krista</forename><surname>Latta</surname></persName>
						</author>
						<author>
							<persName><roleName>MPH</roleName><forename type="first">Isabel</forename><surname>Hurden</surname></persName>
						</author>
						<author>
							<persName><roleName>MPH</roleName><forename type="first">Shamaree</forename><forename type="middle">J</forename><surname>Cromartie</surname></persName>
						</author>
						<author>
							<persName><roleName>MPH</roleName><forename type="first">Allison</forename><forename type="middle">P</forename><surname>Plaxco</surname></persName>
						</author>
						<author>
							<persName><roleName>MPH</roleName><forename type="first">Ayesha</forename><surname>Mukhopadhyay</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Matthew</forename><forename type="middle">P</forename><surname>Smeltzer</surname></persName>
						</author>
						<author role="corresp">
							<persName><forename type="first">Mary</forename><surname>Hulihan</surname></persName>
							<email>mhulihan@cdc.gov.</email>
						</author>
						<author>
							<persName><surname>Drph</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, MPH, Director</roleName><forename type="first">Mandy</forename><forename type="middle">K</forename><surname>Cohen</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, MPH</roleName><forename type="first">Debra</forename><surname>Houry</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Samuel</forename><forename type="middle">F</forename><surname>Posner</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD, MPH, Editor in Chief</roleName><forename type="first">Charlotte</forename><forename type="middle">K</forename><surname>Kent</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, MPH, Acting Executive Editor</roleName><forename type="first">Rachel</forename><surname>Gorwitz</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Jacqueline</forename><surname>Gindler</surname></persName>
						</author>
						<author>
							<persName><roleName>Editor</roleName><forename type="first">Paul</forename><forename type="middle">Z</forename><surname>Siegel</surname></persName>
						</author>
						<author>
							<persName><roleName>Associate Editor</roleName><forename type="first">Mary</forename><surname>Dott</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, MPH</roleName><forename type="first">Online</forename><surname>Editor</surname></persName>
						</author>
						<author>
							<persName><roleName>Managing Editor</roleName><forename type="first">Terisa</forename><forename type="middle">F</forename><surname>Rutledge</surname></persName>
						</author>
						<author>
							<persName><roleName>MS, Lead Technical Writer-Editor</roleName><forename type="first">Teresa</forename><forename type="middle">M</forename><surname>Hood</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Glenn</forename><surname>Damon</surname></persName>
						</author>
						<author>
							<persName><roleName>MS</roleName><forename type="first">Jacqueline</forename><surname>Farley</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD, MPH</roleName><forename type="first">Tiana</forename><surname>Garrett</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ashley</forename><surname>Morici</surname></persName>
						</author>
						<author>
							<persName><roleName>MA</roleName><forename type="first">Stacy</forename><surname>Simon</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Morgan</forename><surname>Thompson</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD, MA</roleName><forename type="first">Suzanne</forename><surname>Webb</surname></persName>
						</author>
						<author>
							<persName><roleName>Acting</roleName><forename type="first">Phyllis</forename><forename type="middle">H</forename><surname>King</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Alexander</forename><forename type="middle">J</forename><surname>Gottardy</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Maureen</forename><forename type="middle">A</forename><surname>Leahy</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Stephen</forename><forename type="middle">R</forename><surname>Spriggs</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Armina</forename><surname>Velarde</surname></persName>
						</author>
						<author>
							<persName><roleName>Visual Information Specialists</roleName><forename type="first">Tong</forename><surname>Yang</surname></persName>
						</author>
						<author>
							<persName><roleName>MBA</roleName><forename type="first">Quang</forename><forename type="middle">M</forename><surname>Doan</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Terraye</forename><forename type="middle">M</forename><surname>Starr</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Moua</forename><surname>Yang</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, Chairman</roleName><forename type="first">Timothy</forename><forename type="middle">F</forename><surname>Jones</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, MPH</roleName><forename type="first">Matthew</forename><forename type="middle">L</forename><surname>Boulton</surname></persName>
						</author>
						<author>
							<persName><roleName>ScD, MA</roleName><forename type="first">Carolyn</forename><surname>Brooks</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Virginia</forename><forename type="middle">A</forename><surname>Caine</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, MPH, MBA</roleName><forename type="first">Jonathan</forename><forename type="middle">E</forename><surname>Fielding</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">David</forename><forename type="middle">W</forename><surname>Fleming</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, DrPH, MPH</roleName><forename type="first">William</forename><forename type="middle">E</forename><surname>Halperin</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, MPH, MPA</roleName><forename type="first">Jewel</forename><surname>Mullen</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Jeff</forename><surname>Niederdeppe</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, MPH</roleName><forename type="first">Patricia</forename><surname>Quinlisk</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, MPH</roleName><forename type="first">Patrick</forename><forename type="middle">L</forename><surname>Remington</surname></persName>
						</author>
						<author>
							<persName><roleName>MS, MA</roleName><forename type="first">Carlos</forename><surname>Roig</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">William</forename><surname>Schaffner</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Morgan</forename><forename type="middle">Bobb</forename><surname>Swanson</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Symone</forename><surname>Hairston</surname></persName>
						</author>
						<author>
							<persName><roleName>MPH</roleName><forename type="first">Acting</forename><surname>Lead</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Health</forename><forename type="middle">Communication</forename><surname>Specialist</surname></persName>
						</author>
						<author>
							<persName><roleName>MPH</roleName><forename type="first">Kiana</forename><surname>Cohen</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Leslie</forename><surname>Hamlin</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Lowery</forename><surname>Johnson</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<note type="raw_affiliation">Atlanta , GA 30329-4027. Information Technology</note>
								<orgName type="department">Information Technology</orgName>
								<address>
									<postCode>30329-4027.</postCode>
									<settlement>Atlanta</settlement>
									<region>GA</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<note type="raw_affiliation">Health Communication Specialists</note>
								<orgName type="department">Health Communication Specialists</orgName>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_FsZnyEQ">Birth Prevalence of Sickle Cell Disease and County-Level Social Vulnerability -Sickle Cell Data Collection Program, 11 States, 2016-2020</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">617FF9C8B1D97B2AFD0EBF9ACF37ABE4</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T06:54+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_GtcGxWZ"><p xml:id="_EgaNJ5w"><s xml:id="_Gg979Ar">Sickle cell disease (SCD) remains a public health priority in the United States because of its association with complex health needs, reduced life expectancy, lifelong disabilities, and high cost of care.</s><s xml:id="_q3tYdRA">A cross-sectional analysis was conducted to calculate the crude and race-specific birth prevalence for SCD using state newborn screening program records during 2016-2020 from 11 Sickle Cell Data Collection program states.</s><s xml:id="_3nUNcu9">The percentage distribution of birth mother residence within Social Vulnerability Index quartiles was derived.</s><s xml:id="_7ZVzP8X">Among 3,305 newborns with confirmed SCD (including 57% with homozygous hemoglobin S or sickle β-null thalassemia across 11 states, 90% of whom were Black or African American [Black], and 4% of whom were Hispanic or Latino), the crude SCD birth prevalence was 4.83 per 10,000 (one in every 2,070) live births and 28.54 per 10,000 (one in every 350) non-Hispanic Black newborns.</s><s xml:id="_rHj7VCX">Approximately two thirds (67%) of mothers of newborns with SCD lived in counties with high or very high levels of social vulnerability; most mothers lived in counties with high or very high levels of vulnerability for racial and ethnic minority status (89%) and housing type and transportation (64%) themes.</s><s xml:id="_SmQTffv">These findings can guide public health, health care systems, and community program planning and implementation that address social determinants of health for infants with SCD.</s><s xml:id="_4zWMnwu">Implementation of tailored interventions, including increasing access to transportation, improving housing, and advancing equity in high vulnerability areas, could facilitate care and improve health outcomes for children with SCD.</s></p><p xml:id="_ypMFz2s"><s xml:id="_XNxS8fy">This report has been corrected.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_8FcZRec">Introduction</head><p xml:id="_aKnkTPb"><s xml:id="_NNFV87d">Sickle cell disease (SCD) is an inherited blood disorder caused by mutations in the hemoglobin subunit beta (HBB) gene and is associated with premature mortality <ref type="bibr" target="#b1">(1)</ref> and significant morbidity, including vasoocclusive pain, stroke, and multiorgan damage.</s><s xml:id="_M4pXAfF">The protective association between variants in HBB and severe Plasmodium falciparum malaria results in a higher prevalence of HBB mutations in geographic areas with high malaria prevalences <ref type="bibr" target="#b2">(2)</ref>.</s><s xml:id="_stMZKH5">The combination of this protective effect and the historical trans-Atlantic slave trade has resulted in SCD primarily affecting Black or African American (Black) persons in the United States, leading to exacerbation of high disease-associated morbidity in groups affected by structural racism and health inequities.</s><s xml:id="_ePBgRKb">Social determinants of health further contribute to poor outcomes among persons with SCD <ref type="bibr" target="#b3">(3,</ref><ref type="bibr" target="#b4">4)</ref>.</s><s xml:id="_nkahpzb">Because of the associated health inequities, high risk of lifelong disabilities, and high cost of care, managing SCD remains a major national public health priority <ref type="bibr" target="#b5">(5)</ref>.</s></p><p xml:id="_3aWWVWn"><s xml:id="_bNvtR4A">Although universal newborn screening for hemoglobinopathies, including SCD, has been implemented nationally since 2006 <ref type="bibr" target="#b6">(6)</ref>, SCD birth prevalence data remain scarce.</s><s xml:id="_NfZxhNn">The most recent race-specific birth prevalence (one in 365 Black newborns) is based on 2007 data <ref type="bibr" target="#b7">(7)</ref>.</s><s xml:id="_3GRUCxv">Data from 2015-2017 indicate an overall SCD birth prevalence of one in 2,024 U.S. newborns <ref type="bibr" target="#b8">(8)</ref>.</s><s xml:id="_f9AFV9R">The CDC-funded Sickle Cell Data Collection (SCDC) program is well suited to estimate SCD birth prevalence.</s><s xml:id="_yUvYS6F">At the time of this analysis, SCDC included 11 state-level surveillance programs from the southern, midwestern, and western United States.</s><s xml:id="_wzXvn5a">The programs collect and analyze data on newborns with SCD, including SCD type and geographic location, allowing for the assessment of county-level socioeconomic conditions that influence health outcomes among infants with SCD.</s><s xml:id="_7xuf2Mh">Identifying these conditions can guide the planning and implementation of public health, health care systems, and community programs supporting persons with SCD.</s><s xml:id="_vKfT7z3">This report analyzed state newborn screening program records from 2016-2020 from 11 SCDC program states to provide updated crude and race-specific SCD prevalence among newborns and to describe the percentage of newborns with SCD by county-level socioeconomic characteristics among these states.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_KhZaRrK">Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_bZ2sFJp">Data Sources</head><p xml:id="_Y3gPj6p"><s xml:id="_vPW2gFd">State newborn screening records from 2016-2020, combined with birth certificate data and confirmation testing results when available, were used to identify the most recent data across 11 SCDC program states (Alabama, California, Colorado, Georgia, Indiana, Michigan, Minnesota, North Carolina, Tennessee, Virginia, and Wisconsin).</s><s xml:id="_WZMFuKY">Newborns with a confirmed diagnosis of SCD were included if the infant's birth and their mother's residence county were within the SCDC program state.</s><s xml:id="_QTFSr6r">Confirmed SCD diagnosis was based on a positive Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory SCD test result reported by a state newborn screening program with confirmatory testing or clinical diagnosis by a physician and documented confirmatory CLIA-certified laboratory testing after the newborn period.</s><s xml:id="_SGkrH4C">The mother's residence county and infant's race, ethnicity, sex, date of birth, and SCD type were extracted from newborn screening records or birth certificate data.</s><s xml:id="_MXxYn5M">Infants' race, ethnicity, and SCD type were based upon state-specific methodologies across newborn screening programs <ref type="bibr" target="#b9">(9)</ref>.</s><s xml:id="_hP7XbN4">The total number of live births and of live births among non-Hispanic Black persons by county were obtained from each state's health department.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_zyHytRe">Data Analysis</head><p xml:id="_ndY4ybF"><s xml:id="_WAp4dv5">Crude SCD birth prevalence (calculated by dividing the number of newborns with SCD by the total number of live births) and SCD birth prevalence among non-Hispanic Black newborns (calculated by dividing the number of Black* newborns with SCD by the total number of live births among non-Hispanic Black † persons) were reported per 10,000 newborns.</s><s xml:id="_kUfHQ6R">Prevalence rates were calculated overall and by state.</s></p><p xml:id="_PpQqpNZ"><s xml:id="_97zTKhd">County Social Vulnerability Index (SVI) characteristics were quantified using the 2020 state-specific SVI databases based on the birth mother's county of residence at birth.</s><s xml:id="_qkHpUnS">The statespecific SVI ranks each county relative to other counties within the state on 16 social factors.</s><s xml:id="_RTPyVWh">Percentile ranking values range from 0 to 1, with higher values indicating greater vulnerability.</s><s xml:id="_SmA7hZS">An overall SVI percentile ranking as well as percentile rankings measured on four themes (socioeconomic status, household characteristics, racial and ethnic minority status, and housing type and transportation) § were categorized into quartiles from least to most vulnerable: low (0 to 0.25), medium (&gt;0.25 to 0.5), high (&gt;0.5 to 0.75), and very high (&gt;0.75 to 1.0) vulnerability.</s><s xml:id="_a49afZr">The percentage distribution of birth mother residence within SVI quartiles was derived for the overall SVI measure and by SVI themes.</s><s xml:id="_XPmDnmT">SAS (version 9.4; SAS Institute) was used for all analyses.</s><s xml:id="_ZfeRVvY">Institutional review boards or ethics committees overseeing each state program either determined the analysis to be outside purview as public health surveillance or exempt and approved a waiver of consent.</s><s xml:id="_tRge7ND">This activity was reviewed by CDC, deemed not research, and was conducted consistent with applicable federal law and CDC policy.</s><s xml:id="_cWm9PcU">¶</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_UDxyTVH">Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_mtr7vdk">Demographics and Birth Prevalence</head><p xml:id="_Cztm4hg"><s xml:id="_qw65hvY">During 2016-2020, a total of 3,305 SCD-affected newborns were recorded across the 11 SCDC program states (Table <ref type="table" target="#tab_2">1</ref>).</s><s xml:id="_KEF4uXt">The highest number of SCD-affected newborns (758) occurred in Georgia, followed by North Carolina (435), California (419), and Alabama (386).</s><s xml:id="_R2qmakX">Approximately 50% of newborns * The number of newborns with SCD was reported to the SCDC programs with separate variables for race and ethnicity.</s><s xml:id="_fDTkMxf">As a result, the numerator in the calculation of SCD birth prevalence includes all Black newborns with SCD, regardless of ethnicity.</s><s xml:id="_tpHaGcJ">† The number of live births was reported to the SCDC programs with a single, combined variable for race and ethnicity.</s><s xml:id="_ZtwmYVE">As a result, the denominator in the calculation of SCD birth prevalence includes only non-Hispanic Black newborns.</s><s xml:id="_zN67Ygj">Because the count of Black newborns with SCD included all ethnicities but the count of all Black live births included non-Hispanic newborns only, the non-Hispanic Black SCD birth prevalence could be overestimated.</s><s xml:id="_Vhf3ac2">§ <ref type="url" target="https://www.atsdr.cdc.gov/placeandhealth/svi/data_documentation_download.html">https://www.atsdr.cdc.gov/placeandhealth/svi/data_documentation_download.html</ref></s><s xml:id="_86d5PSx">¶ 45 C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42 U.S.C.</s><s xml:id="_2fZTMvJ">Sect.</s><s xml:id="_nJVDagN">241(d); 5 U.S.C.</s><s xml:id="_gEpvKzD">Sect.</s><s xml:id="_n9pZGM6">552a; 44 U.S.C.</s><s xml:id="_EFMu3Xf">Sect.</s><s xml:id="_nC2gxYq">3501 et seq.</s></p><p xml:id="_jcF2bHU"><s xml:id="_QF6bnwj">with SCD were male, 90% were Black, and 4% were Hispanic or Latino.</s><s xml:id="_5Q5HHQ5">Overall, 1,882 (57%) infants had homozygous hemoglobin S (HbSS) or sickle β-null thalassemia (HbSβ 0 ), 28% had hemoglobin SC disease, and 10% had sickle β-plus thalassemia (HbSβ + ) or another SCD type.**</s><s xml:id="_nWygxsn">Across the 11 states, crude SCD birth prevalence was 4.83 per 10,000 (one in every 2,070) live births (Table <ref type="table">2</ref>).</s><s xml:id="_YGx6MKx">SCD birth prevalence among non-Hispanic Black newborns was 28.54 per 10,000 (one in every 350) live births.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_cwBy9Fy">Social Vulnerability</head><p xml:id="_UQbyWPM"><s xml:id="_tsBDT3g">Among all mothers of newborns with SCD, approximately two thirds (67%) lived in counties with high or very high social vulnerability (Figure</s></p><p xml:id="_tuNSzZB"><s xml:id="_AJWeQwg">).</s><s xml:id="_UbnCBXB">In five of the 11 SCDC program states, more than one half of birth mothers resided in very high SVI counties (Wisconsin [86%], Indiana [82%], Michigan [61%], Tennessee [58%], and California [56%]) (Supplementary Figure, <ref type="url" target="https://stacks.cdc.gov/view/">https://stacks.cdc.gov/view/</ref></s><s xml:id="_geA4Yvq">cdc/151052).</s><s xml:id="_XewZ6yY">Approximately one half (49%) of mothers of newborns with SCD resided in areas with high or very high socioeconomic vulnerability and household characteristic vulnerability (56%).</s><s xml:id="_VmDKBK3">In addition, approximately two thirds (64%) of mothers resided in counties with high or very high housing type and transportation vulnerability, and 89% resided in counties with high or very high racial and ethnic minority status vulnerability (Figure).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_bs33rRa">Discussion</head><p xml:id="_SfvZSb7"><s xml:id="_TjcEUNK">In this analysis of birth prevalence and social vulnerability ranking of newborns with SCD across 11 SCDC program states, SCD affected one in every 2,070 newborns overall and one in every 350 non-Hispanic Black newborns.</s><s xml:id="_czrYeqs">These findings align with previously reported estimates of SCD affecting one in every 2,024 newborns overall and one in every 365 non-Hispanic Black newborns <ref type="bibr" target="#b7">(7,</ref><ref type="bibr" target="#b8">8)</ref>; however, they expand on those reports by using more recent data from 2016-2020.</s></p><p xml:id="_sWd5ynj"><s xml:id="_Qcz3g3T">The finding that most mothers lived in counties with high or very high SVI highlights the insights that county-level data can provide to public health policymakers when considering the support that community-based programs can deliver to meet the complex health needs of newborns with SCD and their Abbreviations: HbSC = hemoglobin SC disease; HBSS = sickle cell homozygous hemoglobin S; HbSβ 0 = sickle beta-null thalassemia; HbSβ + = sickle beta-plus thalassemia; NH = non-Hispanic; SCD = sickle cell disease; Unk = unknown.</s><s xml:id="_BHn6nfq">* Ethnicity was unknown in 18% of cases; therefore, ethnicity results should be interpreted with caution.</s></p><p xml:id="_6REZyDg"><s xml:id="_AUEfmsf">† Dashes indicate data was censored because counts were &lt;11 in one or more cells.</s></p><p xml:id="_X3USv8E"><s xml:id="_mQD5TGA">TABLE 2. Sickle cell disease birth prevalence overall and among non-Hispanic Black or African American infants -11 Sickle Cell Data Collection program states, 2016-2020 State Total no. of newborns with SCD Total no. of live births Overall crude prevalence* of newborns with SCD No. of Black newborns with SCD † No. of NH Black live births § Prevalence ¶ of NH Black newborns with SCD Alabama 386 292,038 13.22 312 91,467 34.11</s><s xml:id="_hzAVVjH">California 419 2,281,910 1.84 374 136,485 27.40 Colorado 66 540,370 1.22 54 17,541 30.79</s><s xml:id="_ZfskcdR">Georgia 758 633,778 11.96 711 228,199 31.16</s><s xml:id="_GgEdj3e">Indiana 175 406,382 4.31 144 52,827 27.26 Michigan 315 547,020 5.76 284 107,109 26.52 Minnesota 90 335,154 2.69 84 43,514 19.30</s><s xml:id="_Sfe7GbN">North Carolina 435 595,301 7.31 395 143,595 27.51 Tennessee 224 401,622 5.58 215 81,995 26.22 Virginia 321 493,627 6.50 289 104,973 27.53 Wisconsin 116 319,625 3.63 108 33,073 32.66</s><s xml:id="_QQuXwPR">Total 3,305 6,846,827 4.83 2,970 1,040,778 28.54</s></p><p xml:id="_V6qEQrd"><s xml:id="_quYnaDZ">Abbreviations: Black = Black or African American; NH = non-Hispanic; SCD = sickle cell disease; SCDC = Sickle Cell Disease Collection.</s><s xml:id="_cGZTpbQ">* Crude prevalence of newborns with SCD were calculated by dividing the number of newborns with SCD by number of live newborns in each state and multiplying by 10,000.</s><s xml:id="_yWMWSTe">† The number of newborns with SCD was reported to SCDC programs with separate variables for race and ethnicity.</s><s xml:id="_UbdXJCR">As a result, the numerator in the calculation of SCD birth prevalence includes all Black newborns with SCD, regardless of ethnicity.</s><s xml:id="_YJJaybR">§ The number of live births was reported to SCDC programs with a single, combined variable for race and ethnicity.</s><s xml:id="_f5xt3Z3">As a result, the denominator in the calculation of SCD birth prevalence includes only NH Black newborns.</s><s xml:id="_ee3AVtP">¶ Prevalence of NH Black newborns with SCD was calculated by dividing the number of Black newborns with SCD by number of live births among NH Black persons in each state during 2016-2020 and multiplying by 10,000.</s><s xml:id="_dqEbdjD">Birth rates among NH Black persons for Alabama, Colorado, and Indiana should be interpreted with caution because race was unknown for 9%-14% of newborns with SCD in these states; thus, the NH Black SCD birth prevalence for these states could be underestimated.</s></p><p xml:id="_4Xqaff5"><s xml:id="_ZBRQbpf">caregivers.</s><s xml:id="_rmVFQAN">The majority (64%) of mothers of newborns with SCD resided in counties with high or very high housing type and transportation social vulnerability, underscoring potential strategies to serve these communities, including medical transportation programs or development of innovative care models to facilitate access to comprehensive SCD care.</s><s xml:id="_sDYUYtE">For example, improving flexibility in scheduling of medical transportation, providing reimbursement for use of existing public transportation such as rideshares, and partnering with local faith-and community-based organizations for medical transport have the potential to improve access to care.</s><s xml:id="_P2rsPhQ">Moreover, understanding the geographic location of SCD-affected newborns within a state can help guide specialty and primary care efforts to improve access to SCD care.</s><s xml:id="_jdTEhEh">Together, these findings provide data to Medicaid programs, the primary payer for SCD care, † † as they collaborate with state agencies to consider the effect</s></p><p xml:id="_7ZeA3Bz"><s xml:id="_Tj7MvJK">† † <ref type="url" target="https://www.ncbi.nlm.nih.gov/books/NBK547764/">https://www.ncbi.nlm.nih.gov/books/NBK547764/</ref></s><s xml:id="_XVyMQvP">FIGURE.</s><s xml:id="_UPFWGZa">Percentage of mothers of newborns with sickle cell disease (N = 3,305), by overall and theme-specific Social Vulnerability Index quartiles* -11 Sickle Cell Data Collection program states, † 2016-2020 0 10 20 30 40 50 60 70 80 90 100 Overall Socioeconomic status Household characteristics Percentage of mothers SVI themes Housing type and transportation Racial and ethnic minority status Low SVI (0 to 0.25) Medium SVI (&gt;0.25 to 0.5) High SVI (&gt;0.5 to 0.75) Very high SVI (&gt;0.75 to 1.0) Abbreviation: SVI = Social Vulnerability Index.</s><s xml:id="_rw46CnS">* The 2020 state-ranked SVI datasets based on mother's county of residence at birth were used (<ref type="url" target="https://www.atsdr.cdc.gov/placeandhealth/svi/data_documentation_">https://www.atsdr.cdc.gov/placeandhealth/svi/data_documentation_</ref></s><s xml:id="_XZpNEE5">download.html).</s><s xml:id="_8bK4FVg">SVI values were state-specific and ranked each county relative to other counties within a state.</s><s xml:id="_UxMpxJR">The SVI ranks counties based on 16 social factors.</s></p><p xml:id="_dHq6fvD"><s xml:id="_c5H8PhB">Percentile ranking values range from 0 to 1, with higher values indicating greater vulnerability.</s><s xml:id="_K9MbexK">Themes were socioeconomic status (&lt;150% of the federal poverty level, unemployed, housing cost burden, no high school diploma, and no health insurance), household characteristics (age ≥65 years, age ≤17 years, civilian with a disability, single-parent households, and English language proficiency), racial and ethnic minority status (non-Hispanic American Indian or Alaska Native, non-Hispanic Asian, non-Hispanic Black or African American, non-Hispanic Native Hawaiian or other Pacific Islander, non-Hispanic two or more races, Hispanic or Latino of any race, and non-Hispanic other races), and housing type and transportation (multiunit structures, mobile homes, crowding, no vehicle, and group quarters).</s><s xml:id="_xT4vcQm">For 127 (4%) mothers of newborns with sickle cell disease, the county of residence at birth was unknown.</s><s xml:id="_RbxHDCu">† Alabama, California, Colorado, Georgia, Indiana, Michigan, Minnesota, North Carolina, Tennessee, Virginia, and Wisconsin.</s></p><p xml:id="_vdw4fYr"><s xml:id="_WB9uNHW">of housing and transportation vulnerabilities on infants with SCD.</s><s xml:id="_rhcfMwq">These Medicaid programs can also support partnerships created by public health programs, the communities they serve, and community-based organizations to ascertain specific resource needs of SCD-affected populations, as well as where and how resources can be deployed to drive more equitable outcomes.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_JqCaeXb">Limitations</head><p xml:id="_EemdJJ5"><s xml:id="_ZMv7fUQ">The findings in this report are subject to at least four limitations.</s><s xml:id="_CYn5uU6">First, because of the time needed to ascertain SCD type by public health surveillance systems, state newborn screening data are subject to a 3-year time lag.</s><s xml:id="_pSFW2Wc">Despite this lag, SCD counts among newborns did not fluctuate significantly between years.</s><s xml:id="_Q4f9zhU">Second, missing data hampered the ability to further disaggregate race and ethnicity categories, which might be important to understanding differential birth prevalences across states and tailoring programs to different racial and ethnic communities.</s><s xml:id="_wKRpxMP">Third, SVI was examined at the county level as opposed to U.S. Census Bureau tract level, which could mask variations of SVI within counties.</s><s xml:id="_HnGYdk3">Finally, SVI metrics are at the county level rather than the person level and might not reflect a comprehensive assessment of specific services needed by infants with SCD.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_zgShPQq">Implications for Public Health Practice</head><p xml:id="_4pMhbgc"><s xml:id="_w7kfFqd">Understanding characteristics of the geographic residence of infants with SCD and their caregivers is critical to guiding local and state health departments and health agencies in prioritizing and developing programs that can mitigate specific social determinants of health and their attendant inequities.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>TABLE 1 . Number of newborns with sickle cell disease, by sex, race, ethnicity, and confirmed sickle cell disease type (N = 3,305) -11 Sickle Cell Data Collection program states, 2016-2020</head><label>1</label><figDesc><div><p><s xml:id="_MG4SAZK">* Hemoglobin SS disease (HbSS) is usually the most severe type of SCD; children inherit a hemoblobin S gene from each parent.Persons with HbSC disease inherit a hemoglobin S gene from one parent, and a gene for abnormal hemoglobin C from the other parent; HbSC is usually milder than HbSS.Children with HbSβ inherit the hemoglobin S gene from one parent and a β thalassemia gene from the other parent.</s><s xml:id="_ZhUrFTd">HbSβ 0 is usually more severe than is HbSβ</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell>Sex</cell><cell></cell><cell></cell><cell>Race</cell><cell></cell><cell cols="2">Ethnicity*</cell><cell></cell><cell cols="3">Confirmed SCD type</cell><cell></cell></row><row><cell></cell><cell>Total no. of</cell><cell></cell><cell></cell><cell></cell><cell>Black or</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>newborns</cell><cell></cell><cell></cell><cell></cell><cell>African</cell><cell></cell><cell></cell><cell>Hispanic or</cell><cell></cell><cell></cell><cell>HbSS or</cell><cell></cell><cell>HbSβ + or</cell><cell></cell></row><row><cell>State</cell><cell>with SCD</cell><cell>Female</cell><cell>Male</cell><cell>Unk</cell><cell>American</cell><cell>Other</cell><cell>Unk</cell><cell>Latino</cell><cell>NH</cell><cell>Unk</cell><cell>HbSβ 0</cell><cell>HbSC</cell><cell>other</cell><cell>Unk</cell></row><row><cell>Alabama</cell><cell>386</cell><cell>179</cell><cell>159</cell><cell>- †</cell><cell>312</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>52</cell><cell>-</cell><cell>212</cell><cell>85</cell><cell>30</cell><cell>59</cell></row><row><cell>California</cell><cell>419</cell><cell>207</cell><cell>212</cell><cell>-</cell><cell>374</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>371</cell><cell>-</cell><cell>219</cell><cell>133</cell><cell>67</cell><cell>0</cell></row><row><cell>Colorado</cell><cell>66</cell><cell>27</cell><cell>39</cell><cell>-</cell><cell>54</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>56</cell><cell>-</cell><cell>40</cell><cell>18</cell><cell>-</cell><cell>-</cell></row><row><cell>Georgia</cell><cell>758</cell><cell>398</cell><cell>360</cell><cell>-</cell><cell>711</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>667</cell><cell>-</cell><cell>409</cell><cell>207</cell><cell>53</cell><cell>89</cell></row><row><cell>Indiana</cell><cell>175</cell><cell>74</cell><cell>101</cell><cell>-</cell><cell>144</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>142</cell><cell>-</cell><cell>108</cell><cell>51</cell><cell>16</cell><cell>0</cell></row><row><cell>Michigan</cell><cell>315</cell><cell>160</cell><cell>155</cell><cell>-</cell><cell>284</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>250</cell><cell>-</cell><cell>180</cell><cell>86</cell><cell>49</cell><cell>0</cell></row><row><cell>Minnesota</cell><cell>90</cell><cell>46</cell><cell>44</cell><cell>-</cell><cell>84</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>85</cell><cell>-</cell><cell>54</cell><cell>15</cell><cell>-</cell><cell>-</cell></row><row><cell>North</cell><cell>435</cell><cell>196</cell><cell>239</cell><cell>-</cell><cell>395</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>412</cell><cell>-</cell><cell>268</cell><cell>129</cell><cell>19</cell><cell>19</cell></row><row><cell>Carolina</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Tennessee</cell><cell>224</cell><cell>113</cell><cell>111</cell><cell>-</cell><cell>215</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>212</cell><cell>-</cell><cell>136</cell><cell>63</cell><cell>25</cell><cell>0</cell></row><row><cell>Virginia</cell><cell>321</cell><cell>161</cell><cell>159</cell><cell>-</cell><cell>289</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>218</cell><cell>-</cell><cell>188</cell><cell>106</cell><cell>27</cell><cell>0</cell></row><row><cell>Wisconsin</cell><cell>116</cell><cell>56</cell><cell>60</cell><cell>-</cell><cell>108</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>104</cell><cell>-</cell><cell>68</cell><cell>28</cell><cell>-</cell><cell>-</cell></row><row><cell>Total (row %)</cell><cell>3,305</cell><cell>1,617</cell><cell>1,639</cell><cell>49</cell><cell>2,970</cell><cell>198</cell><cell>137</cell><cell>134</cell><cell>2,569</cell><cell>602</cell><cell>1,882</cell><cell>921</cell><cell>317</cell><cell>185</cell></row><row><cell></cell><cell>(100)</cell><cell>(48.9)</cell><cell>(49.6)</cell><cell>(1.5)</cell><cell>(89.9)</cell><cell>(6.0)</cell><cell>(4.1)</cell><cell>(4.1)</cell><cell>(77.7)</cell><cell>(18.2)</cell><cell>(56.9)</cell><cell>(27.9)</cell><cell>(9.6)</cell><cell>(5.6)</cell></row></table><note xml:id="_qFgDUJD"><p>*</p><p><s xml:id="_zSz6nPx">+ .</s><s xml:id="_MMU6BgN">Rarer SCD types include HbSD, HbSE, and HbSO, in which an abnormal D, E, or O hemoglobin gene is inherited from one parent, and the hemoglobin S gene is inherited from the other parent.</s><s xml:id="_4zNDnGw">https://www.cdc.gov/</s><s xml:id="_KZ9Xr8A">ncbddd/sicklecell/facts.html</s></p></note></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xml:id="_93xexYF"><p xml:id="_6ptd75f"><s xml:id="_WcP3kFf">All authors have completed and submitted the <rs type="institution">International Committee of Medical Journal</rs> Editors form for disclosure of potential conflicts of interest.</s><s xml:id="_XKZAKjn"><rs type="person">Sophia S. Horiuchi</rs> reports ownership of Natera stock and stock options and of <rs type="institution">Roche</rs> stock by her spouse.</s><s xml:id="_DF7zwKZ"><rs type="person">Mariam Kayle</rs> reports institutional support from <rs type="funder">Agios Medical Education Program</rs> and <rs type="funder">Novo Nordisk Independent Medical Education Activity</rs> to support the 11th Annual Sickle Cell Conference, September 8-9, 2023; receipt of consulting fees from <rs type="institution">Loyola University</rs>; receipt of honorarium for being an ad hoc reviewer from the <rs type="funder">National Institutes of Health (NIH), Center for Scientific Review, Social and Environmental Determinants of Health Study Section</rs>; and uncompensated membership in the <rs type="funder">American Society of Hematology Research Collaborative Data Hub Oversight Group</rs>, <rs type="funder">Sickle Cell Disease Subcommittee</rs>.</s><s xml:id="_R66jWkM"><rs type="person">Carri S. Polick</rs> reports support from the <rs type="funder">Veterans Administration and Duke University Clinical and Translational Science Institute</rs>.</s><s xml:id="_vuNxGX8"><rs type="person">Ashima Singh</rs> reports institutional support from <rs type="funder">NIH</rs>, <rs type="funder">National Heart, Lung, and Blood Institute</rs>, the <rs type="funder">National Institute of Neurological Disorders and Stroke</rs>, and the <rs type="funder">Health Resources and Services Administration (HRSA)</rs> <rs type="programName">Sickle Cell Treatment Demonstration Program</rs>.</s><s xml:id="_sGGyFfv"><rs type="person">John J. Strouse</rs> reports institutional support from the <rs type="funder">HRSA Southeast Region Coordinating Center Sickle Cell Treatment Demonstration Program</rs> and the <rs type="funder">North Carolina State Department of Health Sickle Cell Syndrome Program</rs> for the <rs type="funder">Duke Adult and Pediatric Sickle Cell Program</rs>; royalties from</s></p><p xml:id="_wFu72tn"><s xml:id="_TEWBftQ"><rs type="person">UpToDate</rs> for preparation of guidance on the use of hydroxyurea for sickle cell disease (SCD); consulting fees for GLG telephone consultation on SCD and Guidepoint telephone consultation on SCD; receipt of honoraria from the <rs type="institution">University of Rochester-Equity in Sickle Cell Disease Care</rs>; payment for medical legal expert testimony from <rs type="institution">Emory University</rs> in a case involving emergency department care of an adult with sickle beta thalassemia; travel support from the <rs type="funder">American Society of Hematology Sickle Cell Learning Community Meeting and Sickle Cell Disease Association of America Meeting</rs> to speak on behalf of the <rs type="funder">American Society of Hematology</rs> and travel support from the <rs type="funder">American Thrombosis Hemostasis Network Data Summit</rs> as an invited speaker on gene therapy for SCD: Design for Equity; payment for participation on a data safety monitoring board for disc medicines for phase 1 trial planning for bitopertin for SCD; and service as vice president of the <rs type="institution">Sickle Cell Adult Provider Network</rs>.</s><s xml:id="_52F4s9T">No other potential conflicts of interest were disclosed.</s></p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_yqGYsaC">
					<orgName type="program" subtype="full">Sickle Cell Treatment Demonstration Program</orgName>
				</org>
			</listOrg>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_QWAJmwM">Summary</head><p xml:id="_rxPmnKf"><s xml:id="_BGh4h5a">What is already known about the topic?</s></p><p xml:id="_y7WK8Wa"><s xml:id="_YS2Y2cm">Approximately one in every 365 Black or African American (Black) newborns in the United States has sickle cell disease (SCD), a condition associated with complex health needs.</s></p><p xml:id="_PVnvFgj"><s xml:id="_bQhU3jQ">What is added by this report?</s><s xml:id="_5MZh7t6">Specifically, these data highlight the potential need to consider tailored interventions in high vulnerability areas to increase access to transportation, improve housing, and advance equity for infants with SCD.</s><s xml:id="_trTYnRA">Developing programs in partnership with communities and community-based organizations is critical to allocating needed resources and determining how they might be effective in improving health outcomes for children with SCD.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Susan</forename><forename type="middle">B</forename><surname>Meister</surname></persName>
		</author>
		<idno type="DOI">10.5152/dir.2018.18050</idno>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<pubPlace>Memphis, Tennessee</pubPlace>
		</imprint>
		<respStmt>
			<orgName>Child Health Evaluation and Research Center, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan ; Michigan Department of Health and Human Services; 17 Virginia Department of Health; 18 Division of Epidemiology, Biostatistics and Environmental Health, School of Public Health, The University of Memphis ; Division of Blood Disorders and Public Health Genomics, National Center on Birth Defects and Developmental Disabilities, CDC</orgName>
		</respStmt>
	</monogr>
	<note type="raw_reference">Susan B. Meister Child Health Evaluation and Research Center, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan; 16 Michigan Department of Health and Human Services; 17 Virginia Department of Health; 18 Division of Epidemiology, Biostatistics and Environmental Health, School of Public Health, The University of Memphis, Memphis, Tennessee; 19 Division of Blood Disorders and Public Health Genomics, National Center on Birth Defects and Developmental Disabilities, CDC. References</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main" xml:id="_EJy5PaA">Trends in sickle cell diseaserelated mortality in the United States, 1979 to 2017</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Payne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Mehal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Chapman</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.annemergmed.2020.08.009</idno>
		<idno type="PMID">32928459</idno>
		<ptr target="https://doi.org/10.1016/j.annemergmed.2020.08.009" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_PcTAWes">Ann Emerg Med</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="issue">3S</biblScope>
			<biblScope unit="page" from="28" to="36" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Payne AB, Mehal JM, Chapman C, et al. Trends in sickle cell disease- related mortality in the United States, 1979 to 2017. Ann Emerg Med 2020;76(3S):S28-36. PMID:32928459 https://doi.org/10.1016/j. annemergmed.2020.08.009</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main" xml:id="_pAr7pB2">Evolutionary history of sickle-cell mutation: implications for global genetic medicine</title>
		<author>
			<persName><forename type="first">K</forename><surname>Esoh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Wonkam</surname></persName>
		</author>
		<idno type="DOI">10.1093/hmg/ddab004</idno>
		<idno type="PMID">33461216</idno>
		<ptr target="https://doi.org/10.1093/hmg/ddab004" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_v6f9636">Hum Mol Genet</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">R1</biblScope>
			<biblScope unit="page" from="R119" to="128" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Esoh K, Wonkam A. Evolutionary history of sickle-cell mutation: implications for global genetic medicine. Hum Mol Genet 2021;30(R1):R119-28. PMID:33461216 https://doi.org/10.1093/hmg/ddab004</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main" xml:id="_j7DGW5D">Perspectives of individuals with sickle cell disease on barriers to care</title>
		<author>
			<persName><forename type="first">S</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Masese</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0265342</idno>
		<idno type="PMID">35320302</idno>
		<ptr target="https://doi.org/10.1371/journal.pone.0265342" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_t6BynCC">PLoS One</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page">265342</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Phillips S, Chen Y, Masese R, et al. Perspectives of individuals with sickle cell disease on barriers to care. PLoS One 2022;17:e0265342. PMID:35320302 https://doi.org/10.1371/journal.pone.0265342</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main" xml:id="_nWsa58v">Emergency department management of acute pain episodes in sickle cell disease</title>
		<author>
			<persName><forename type="first">P</forename><surname>Tanabe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Myers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zosel</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1553-2712.2007.tb01801.x</idno>
		<idno type="PMID">17389246</idno>
		<ptr target="https://doi.org/10.1111/j.1553-2712.2007.tb01801.x" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_BCMkXWg">Acad Emerg Med</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="419" to="425" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Tanabe P, Myers R, Zosel A, et al. Emergency department management of acute pain episodes in sickle cell disease. Acad Emerg Med 2007;14:419-25. PMID:17389246 https://doi.org/10.1111/j.1553-2712.2007.tb01801.x</note>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<author>
			<persName><surname>Cdc</surname></persName>
		</author>
		<idno type="DOI">10.1037/e409722005-001</idno>
		<ptr target="https://www.cdc.gov/ncbddd/sicklecell/about.html#:~:text=CDC%20strives%20to%20educate%20people,SCD%20among%20the%20general%20public" />
		<title level="m" xml:id="_f8zrftA">Sickle cell disease: about CDC&apos;s work on sickle cell disease</title>
		<meeting><address><addrLine>Atlanta, GA</addrLine></address></meeting>
		<imprint>
			<publisher>US Department of Health and Human Services, CDC</publisher>
			<date type="published" when="2023-07-17">2023. July 17, 2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">CDC. Sickle cell disease: about CDC&apos;s work on sickle cell disease. Atlanta, GA: US Department of Health and Human Services, CDC; 2023. Accessed July 17, 2023. https://www.cdc.gov/ncbddd/sicklecell/about. html#:~:text=CDC%20strives%20to%20educate%20people,SCD%20 among%20the%20general%20public</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main" xml:id="_wbpKpzu">History and current status of newborn screening for hemoglobinopathies</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Benson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Therrell</surname><genName>Jr</genName></persName>
		</author>
		<idno type="DOI">10.1053/j.semperi.2009.12.006</idno>
		<idno type="PMID">20207263</idno>
		<ptr target="https://doi.org/10.1053/j.semperi.2009.12.006" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_X4x8tJE">Semin Perinatol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="134" to="144" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Benson JM, Therrell BL Jr. History and current status of newborn screening for hemoglobinopathies. Semin Perinatol 2010;34:134-44. PMID:20207263 https://doi.org/10.1053/j.semperi.2009.12.006</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main" xml:id="_nYmUZtR">Population estimates of sickle cell disease in the U.S</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Hassell</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.amepre.2009.12.022</idno>
		<idno type="PMID">20331952</idno>
		<ptr target="https://doi.org/10.1016/j.amepre.2009.12.022" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_TxTDTmZ">Am J Prev Med</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="512" to="521" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
	<note type="raw_reference">Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med 2010;38(Suppl):S512-21. PMID:20331952 https://doi. org/10.1016/j.amepre.2009.12.022</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main" xml:id="_puqEy5W">Infants with congenital disorders identified through newborn screening-United States, 2015-2017</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Sontag</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Yusuf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Grosse</surname></persName>
		</author>
		<idno type="DOI">10.15585/mmwr.mm6936a6</idno>
		<idno type="PMID">32915168</idno>
		<ptr target="https://doi.org/10.15585/mmwr.mm6936a6" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_5rW263k">MMWR Morb Mortal Wkly Rep</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="1265" to="1268" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sontag MK, Yusuf C, Grosse SD, et al. Infants with congenital disorders identified through newborn screening-United States, 2015-2017. MMWR Morb Mortal Wkly Rep 2020;69:1265-8. PMID:32915168 https://doi.org/10.15585/mmwr.mm6936a6</note>
</biblStruct>

<biblStruct xml:id="b9">
	<monogr>
		<title level="m" type="main" xml:id="_EnJhzuN">Hemoglobinopathies: current practices for screening, confirmation and follow-up</title>
		<author>
			<persName><surname>Aphl</surname></persName>
		</author>
		<ptr target="https://www.aphl.org/aboutAPHL/publications/Documents/NBS_HemoglobinopathyTesting_122015.pdf" />
		<imprint>
			<date type="published" when="2015-08-22">2015. August 22, 2023</date>
			<publisher>Association of Public Health Laboratories</publisher>
			<pubPlace>Silver Spring, MD</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">APHL. Hemoglobinopathies: current practices for screening, confirmation and follow-up. Silver Spring, MD: Association of Public Health Laboratories; 2015. Accessed August 22, 2023. https://www.aphl.org/aboutAPHL/publications/Documents/NBS_ HemoglobinopathyTesting_122015.pdf</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
